A phase I/II trial of oxidized autologous tumor vaccines during the watch and wait phase of chronic lymphocytic leukemia
Based on their activity in patients with advanced stage chronic lymphocytic leukemia (CLL), a phase I/II study was designed to evaluate the feasibility, safety, and efficacy of autologous vaccines made from oxidized tumor cells in patients with earlier stage CLL, and to determine an optimal schedule...
Gespeichert in:
| Veröffentlicht in: | Cancer Immunology, Immunotherapy Immunotherapy, 2005-07, Vol.54 (7), p.635-646 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 646 |
|---|---|
| container_issue | 7 |
| container_start_page | 635 |
| container_title | Cancer Immunology, Immunotherapy |
| container_volume | 54 |
| creator | SPANER, David E HAMMOND, Caitlin MENA, Jenny FODEN, Cindy DEABREU, Andrea |
| description | Based on their activity in patients with advanced stage chronic lymphocytic leukemia (CLL), a phase I/II study was designed to evaluate the feasibility, safety, and efficacy of autologous vaccines made from oxidized tumor cells in patients with earlier stage CLL, and to determine an optimal schedule of injections. Eighteen patients (at risk for disease progression and with white blood cell counts between 15 and 100 x 10(6) cells/ml) were injected intramuscularly with 10 ml of oxidized autologous blood (composed mainly of CLL cells) either 12 times over 6 weeks (group 1), 12 times over 16 days (group 2), or 4 times over 6 weeks (group 3). Fourteen out of eighteen patients had Rai stage 0-II disease, while 4/18 had stage III-IV disease but did not require conventional treatment. Partial clinical responses, associated with enhanced anti-tumor T cell activity in vitro, were observed in 5/18 patients of whom three were in group 2. Stable disease was observed in six patients while disease progression appeared not to be affected in the remaining patients. Toxicity was minimal. Vaccination with oxidized autologous tumor cells appears worthy of further investigation and may be a potential alternative to a "watch and wait" strategy for selected CLL patients. |
| doi_str_mv | 10.1007/s00262-004-0626-5 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11034307</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>846022921</sourcerecordid><originalsourceid>FETCH-LOGICAL-c443t-a5edf695ce596fd8f29c42dd205d8c675f2504fe0f305543505d4aff6de68a103</originalsourceid><addsrcrecordid>eNqFkUuLFDEUhYMoTjv6A9xIEHRXTt6pWskw-GgYcKPrEPPoyliVtElqnPbXm6YLR924yuHe7x5y7wHgOUZvMELyoiBEBOkQYh0SRHT8AdhgRlul5_gh2CDKUCdb-ww8KeWmCYKG4TE4w3zAPZJ8A-4u4X7UxcHtxXYLaw56gsnDdBds-Oks1EtNU9qlpcC6zCnDW21MiK5Au-QQd7CODv7Q1YxQR9tUqKthczFjTjEYOB3m_ZjMoR61W765Oein4JHXU3HP1vccfHn_7vPVx-7604ft1eV1ZxijtdPcWS8GbhwfhLe9J4NhxFqCuO2NkNwTjph3yFPEOaO81Zn2Xlgneo0RPQdvT7775evsrHGxZj2pfQ6zzgeVdFB_d2IY1S7dKtyGGUWyObxeHXL6vrhS1RyKcdOko2t3UUL2osdc_BfEklIiOW3gy3_Am7Tk2M6gCG4rYEZ4g_AJMjmVkp3__WeM1DF-dYpftVjVMX51nHnx57L3E2veDXi1AroYPfmsownlnhNS9lxi-guScLlq</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>213501425</pqid></control><display><type>article</type><title>A phase I/II trial of oxidized autologous tumor vaccines during the watch and wait phase of chronic lymphocytic leukemia</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><source>PubMed Central</source><creator>SPANER, David E ; HAMMOND, Caitlin ; MENA, Jenny ; FODEN, Cindy ; DEABREU, Andrea</creator><creatorcontrib>SPANER, David E ; HAMMOND, Caitlin ; MENA, Jenny ; FODEN, Cindy ; DEABREU, Andrea</creatorcontrib><description>Based on their activity in patients with advanced stage chronic lymphocytic leukemia (CLL), a phase I/II study was designed to evaluate the feasibility, safety, and efficacy of autologous vaccines made from oxidized tumor cells in patients with earlier stage CLL, and to determine an optimal schedule of injections. Eighteen patients (at risk for disease progression and with white blood cell counts between 15 and 100 x 10(6) cells/ml) were injected intramuscularly with 10 ml of oxidized autologous blood (composed mainly of CLL cells) either 12 times over 6 weeks (group 1), 12 times over 16 days (group 2), or 4 times over 6 weeks (group 3). Fourteen out of eighteen patients had Rai stage 0-II disease, while 4/18 had stage III-IV disease but did not require conventional treatment. Partial clinical responses, associated with enhanced anti-tumor T cell activity in vitro, were observed in 5/18 patients of whom three were in group 2. Stable disease was observed in six patients while disease progression appeared not to be affected in the remaining patients. Toxicity was minimal. Vaccination with oxidized autologous tumor cells appears worthy of further investigation and may be a potential alternative to a "watch and wait" strategy for selected CLL patients.</description><identifier>ISSN: 0340-7004</identifier><identifier>EISSN: 1432-0851</identifier><identifier>DOI: 10.1007/s00262-004-0626-5</identifier><identifier>PMID: 15918075</identifier><identifier>CODEN: CIIMDN</identifier><language>eng</language><publisher>Berlin: Springer</publisher><subject>Adult ; Aged ; Antigens, CD - immunology ; Antigens, CD - metabolism ; Antineoplastic agents ; B7-1 Antigen - immunology ; B7-1 Antigen - metabolism ; B7-2 Antigen ; Biological and medical sciences ; Cancer Vaccines - therapeutic use ; Feasibility Studies ; Female ; Hematologic and hematopoietic diseases ; Humans ; Immunotherapy ; Leukemia, Lymphocytic, Chronic, B-Cell - immunology ; Leukemia, Lymphocytic, Chronic, B-Cell - therapy ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Male ; Medical sciences ; Membrane Glycoproteins - immunology ; Membrane Glycoproteins - metabolism ; Middle Aged ; Original ; Pharmacology. Drug treatments ; T-Lymphocytes - immunology ; T-Lymphocytes, Cytotoxic - immunology ; Transplantation, Autologous ; Tumor Cells, Cultured</subject><ispartof>Cancer Immunology, Immunotherapy, 2005-07, Vol.54 (7), p.635-646</ispartof><rights>2005 INIST-CNRS</rights><rights>Springer-Verlag 2005</rights><rights>Springer-Verlag 2004</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c443t-a5edf695ce596fd8f29c42dd205d8c675f2504fe0f305543505d4aff6de68a103</citedby><cites>FETCH-LOGICAL-c443t-a5edf695ce596fd8f29c42dd205d8c675f2504fe0f305543505d4aff6de68a103</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11034307/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11034307/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16778571$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15918075$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SPANER, David E</creatorcontrib><creatorcontrib>HAMMOND, Caitlin</creatorcontrib><creatorcontrib>MENA, Jenny</creatorcontrib><creatorcontrib>FODEN, Cindy</creatorcontrib><creatorcontrib>DEABREU, Andrea</creatorcontrib><title>A phase I/II trial of oxidized autologous tumor vaccines during the watch and wait phase of chronic lymphocytic leukemia</title><title>Cancer Immunology, Immunotherapy</title><addtitle>Cancer Immunol Immunother</addtitle><description>Based on their activity in patients with advanced stage chronic lymphocytic leukemia (CLL), a phase I/II study was designed to evaluate the feasibility, safety, and efficacy of autologous vaccines made from oxidized tumor cells in patients with earlier stage CLL, and to determine an optimal schedule of injections. Eighteen patients (at risk for disease progression and with white blood cell counts between 15 and 100 x 10(6) cells/ml) were injected intramuscularly with 10 ml of oxidized autologous blood (composed mainly of CLL cells) either 12 times over 6 weeks (group 1), 12 times over 16 days (group 2), or 4 times over 6 weeks (group 3). Fourteen out of eighteen patients had Rai stage 0-II disease, while 4/18 had stage III-IV disease but did not require conventional treatment. Partial clinical responses, associated with enhanced anti-tumor T cell activity in vitro, were observed in 5/18 patients of whom three were in group 2. Stable disease was observed in six patients while disease progression appeared not to be affected in the remaining patients. Toxicity was minimal. Vaccination with oxidized autologous tumor cells appears worthy of further investigation and may be a potential alternative to a "watch and wait" strategy for selected CLL patients.</description><subject>Adult</subject><subject>Aged</subject><subject>Antigens, CD - immunology</subject><subject>Antigens, CD - metabolism</subject><subject>Antineoplastic agents</subject><subject>B7-1 Antigen - immunology</subject><subject>B7-1 Antigen - metabolism</subject><subject>B7-2 Antigen</subject><subject>Biological and medical sciences</subject><subject>Cancer Vaccines - therapeutic use</subject><subject>Feasibility Studies</subject><subject>Female</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Leukemia, Lymphocytic, Chronic, B-Cell - immunology</subject><subject>Leukemia, Lymphocytic, Chronic, B-Cell - therapy</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Membrane Glycoproteins - immunology</subject><subject>Membrane Glycoproteins - metabolism</subject><subject>Middle Aged</subject><subject>Original</subject><subject>Pharmacology. Drug treatments</subject><subject>T-Lymphocytes - immunology</subject><subject>T-Lymphocytes, Cytotoxic - immunology</subject><subject>Transplantation, Autologous</subject><subject>Tumor Cells, Cultured</subject><issn>0340-7004</issn><issn>1432-0851</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqFkUuLFDEUhYMoTjv6A9xIEHRXTt6pWskw-GgYcKPrEPPoyliVtElqnPbXm6YLR924yuHe7x5y7wHgOUZvMELyoiBEBOkQYh0SRHT8AdhgRlul5_gh2CDKUCdb-ww8KeWmCYKG4TE4w3zAPZJ8A-4u4X7UxcHtxXYLaw56gsnDdBds-Oks1EtNU9qlpcC6zCnDW21MiK5Au-QQd7CODv7Q1YxQR9tUqKthczFjTjEYOB3m_ZjMoR61W765Oein4JHXU3HP1vccfHn_7vPVx-7604ft1eV1ZxijtdPcWS8GbhwfhLe9J4NhxFqCuO2NkNwTjph3yFPEOaO81Zn2Xlgneo0RPQdvT7775evsrHGxZj2pfQ6zzgeVdFB_d2IY1S7dKtyGGUWyObxeHXL6vrhS1RyKcdOko2t3UUL2osdc_BfEklIiOW3gy3_Am7Tk2M6gCG4rYEZ4g_AJMjmVkp3__WeM1DF-dYpftVjVMX51nHnx57L3E2veDXi1AroYPfmsownlnhNS9lxi-guScLlq</recordid><startdate>20050701</startdate><enddate>20050701</enddate><creator>SPANER, David E</creator><creator>HAMMOND, Caitlin</creator><creator>MENA, Jenny</creator><creator>FODEN, Cindy</creator><creator>DEABREU, Andrea</creator><general>Springer</general><general>Springer Nature B.V</general><general>Springer-Verlag</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20050701</creationdate><title>A phase I/II trial of oxidized autologous tumor vaccines during the watch and wait phase of chronic lymphocytic leukemia</title><author>SPANER, David E ; HAMMOND, Caitlin ; MENA, Jenny ; FODEN, Cindy ; DEABREU, Andrea</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c443t-a5edf695ce596fd8f29c42dd205d8c675f2504fe0f305543505d4aff6de68a103</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antigens, CD - immunology</topic><topic>Antigens, CD - metabolism</topic><topic>Antineoplastic agents</topic><topic>B7-1 Antigen - immunology</topic><topic>B7-1 Antigen - metabolism</topic><topic>B7-2 Antigen</topic><topic>Biological and medical sciences</topic><topic>Cancer Vaccines - therapeutic use</topic><topic>Feasibility Studies</topic><topic>Female</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Leukemia, Lymphocytic, Chronic, B-Cell - immunology</topic><topic>Leukemia, Lymphocytic, Chronic, B-Cell - therapy</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Membrane Glycoproteins - immunology</topic><topic>Membrane Glycoproteins - metabolism</topic><topic>Middle Aged</topic><topic>Original</topic><topic>Pharmacology. Drug treatments</topic><topic>T-Lymphocytes - immunology</topic><topic>T-Lymphocytes, Cytotoxic - immunology</topic><topic>Transplantation, Autologous</topic><topic>Tumor Cells, Cultured</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SPANER, David E</creatorcontrib><creatorcontrib>HAMMOND, Caitlin</creatorcontrib><creatorcontrib>MENA, Jenny</creatorcontrib><creatorcontrib>FODEN, Cindy</creatorcontrib><creatorcontrib>DEABREU, Andrea</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer Immunology, Immunotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SPANER, David E</au><au>HAMMOND, Caitlin</au><au>MENA, Jenny</au><au>FODEN, Cindy</au><au>DEABREU, Andrea</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A phase I/II trial of oxidized autologous tumor vaccines during the watch and wait phase of chronic lymphocytic leukemia</atitle><jtitle>Cancer Immunology, Immunotherapy</jtitle><addtitle>Cancer Immunol Immunother</addtitle><date>2005-07-01</date><risdate>2005</risdate><volume>54</volume><issue>7</issue><spage>635</spage><epage>646</epage><pages>635-646</pages><issn>0340-7004</issn><eissn>1432-0851</eissn><coden>CIIMDN</coden><abstract>Based on their activity in patients with advanced stage chronic lymphocytic leukemia (CLL), a phase I/II study was designed to evaluate the feasibility, safety, and efficacy of autologous vaccines made from oxidized tumor cells in patients with earlier stage CLL, and to determine an optimal schedule of injections. Eighteen patients (at risk for disease progression and with white blood cell counts between 15 and 100 x 10(6) cells/ml) were injected intramuscularly with 10 ml of oxidized autologous blood (composed mainly of CLL cells) either 12 times over 6 weeks (group 1), 12 times over 16 days (group 2), or 4 times over 6 weeks (group 3). Fourteen out of eighteen patients had Rai stage 0-II disease, while 4/18 had stage III-IV disease but did not require conventional treatment. Partial clinical responses, associated with enhanced anti-tumor T cell activity in vitro, were observed in 5/18 patients of whom three were in group 2. Stable disease was observed in six patients while disease progression appeared not to be affected in the remaining patients. Toxicity was minimal. Vaccination with oxidized autologous tumor cells appears worthy of further investigation and may be a potential alternative to a "watch and wait" strategy for selected CLL patients.</abstract><cop>Berlin</cop><pub>Springer</pub><pmid>15918075</pmid><doi>10.1007/s00262-004-0626-5</doi><tpages>12</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0340-7004 |
| ispartof | Cancer Immunology, Immunotherapy, 2005-07, Vol.54 (7), p.635-646 |
| issn | 0340-7004 1432-0851 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11034307 |
| source | MEDLINE; Springer Nature - Complete Springer Journals; PubMed Central |
| subjects | Adult Aged Antigens, CD - immunology Antigens, CD - metabolism Antineoplastic agents B7-1 Antigen - immunology B7-1 Antigen - metabolism B7-2 Antigen Biological and medical sciences Cancer Vaccines - therapeutic use Feasibility Studies Female Hematologic and hematopoietic diseases Humans Immunotherapy Leukemia, Lymphocytic, Chronic, B-Cell - immunology Leukemia, Lymphocytic, Chronic, B-Cell - therapy Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Male Medical sciences Membrane Glycoproteins - immunology Membrane Glycoproteins - metabolism Middle Aged Original Pharmacology. Drug treatments T-Lymphocytes - immunology T-Lymphocytes, Cytotoxic - immunology Transplantation, Autologous Tumor Cells, Cultured |
| title | A phase I/II trial of oxidized autologous tumor vaccines during the watch and wait phase of chronic lymphocytic leukemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T15%3A41%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20phase%20I/II%20trial%20of%20oxidized%20autologous%20tumor%20vaccines%20during%20the%20watch%20and%20wait%20phase%20of%20chronic%20lymphocytic%20leukemia&rft.jtitle=Cancer%20Immunology,%20Immunotherapy&rft.au=SPANER,%20David%20E&rft.date=2005-07-01&rft.volume=54&rft.issue=7&rft.spage=635&rft.epage=646&rft.pages=635-646&rft.issn=0340-7004&rft.eissn=1432-0851&rft.coden=CIIMDN&rft_id=info:doi/10.1007/s00262-004-0626-5&rft_dat=%3Cproquest_pubme%3E846022921%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=213501425&rft_id=info:pmid/15918075&rfr_iscdi=true |